This trial is designed as a blinded, randomized and parallel group study to investigate the clinically recommended dosage for ASP7374 based on the comparison of the immunogenicity and safety among two doses of subcutaneous ASP7374 and one dose of intramuscular ASP7374 in healthy adults.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Enrollment
165
subcutaneous and intramuscular
Unnamed facility
Kyushu, Japan
Immunogenicity: HI antibody titer
Time frame: Day 29
Safety: Incidence of Adverse events, vital signs and laboratory tests
Time frame: 28 days post-vaccination
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.